Jill M. Broadfoot
Jill Broadfoot, age 64, has served as our director since June 2025. Ms. Broadfoot currently serves as the Chief Financial Officer of aTyr Pharma, Inc., a position she has held since July 2018. Prior to joining aTyr Pharma, Ms. Broadfoot served as Chief Financial Officer along with other senior financial roles in a variety of pharmaceutical and nutraceutical cannabis companies, most notably GW Pharmaceuticals, where she was responsible for establishing research and commercial operations in the U.S. and research operations in Canada and Spain as well as the establishment of corporate governance, manufacturing, finance and accounting, information technology and investor relations functions, among others. Prior to joining GW Pharmaceuticals, Ms. Broadfoot served as Chief Financial Officer of Vical Inc., where she had oversight of finance, investor relations, manufacturing, information technology, human resources, and business development. Prior to that, Ms. Broadfoot held various senior financial positions at DJO Global, Inc., and served as an audit manager at Ernst & Young LLP. Ms. Broadfoot is a member of the board of directors of Talphera, Inc., a publicly traded specialty pharmaceutical company since 2021. She also served on the board of directors of Otonomy, Inc. from 2021 to 2023 and Angiocrine Bioscience, Inc. from 2023 to 2025. Ms. Broadfoot holds a B.S. in Business Administration and Accounting from San Diego State University and is a Certified Public Accountant (Inactive). Ms. Broadfoot’s financial and business expertise, including her diversified background in finance, operations, information technology and business development, provides her with the qualifications and skills to serve on our board of directors.
